Novacyt S.A. (CDI) (NCYT)

Sector:

Health Care

Index:

FTSE AIM All-Share

118.70p
   
  • Change Today:
    -2.30p
  • 52 Week High: 434.90
  • 52 Week Low: 107.50
  • Currency: UK Pounds
  • Shares Issued: 70.63m
  • Volume: 70,609
  • Market Cap: £83.83m
  • RiskGrade: 453

NCYT Overview

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -8.1% 4.6%
ROCE n/a  
Latest F'cast
P/E n/a 60.7
PEG n/a n/a
Pr/Revenue 88.4 1.8
Pr/Book 0.6  
Latest F'cast
Revenue -99.7% -42.2%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

NCYT Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 12.75 (3.49) (15.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-18 13.72 (2.08) (6.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-19 11.47 (3.43) (8.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 277.20 165.17 194.00p 4.4 n/a n/a n/a 0.0%
31-Dec-21 95.78 (9.83) (0.14)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

NCYT Forecasts

Year Ending Revenue ( m) Pre-tax ( m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-22 46.72 2.13 2.37¢ 59.4 n/a n/a n/a 0.0%
31-Dec-23 n/a n/a n/a n/a n/a -100% n/a 0.0%

Copyright © 2022 FactSet Research Systems Inc. All rights reserved.

NCYT Company Announcements

Launch of first fully lyophilised PROmate® ... 04-Aug-2022 07:00 RNS
Liquidity Agreement and Total Voting Rights 01-Aug-2022 14:30 RNS
Launch of research-use-only adenovirus F41 assay 28-Jul-2022 07:00 RNS

NCYT ShareCast News

Novacyt's exsig Covid-19 PCR test receives UK ap... 15-Jul-2022 ShareCast
Novacyt gets another Covid-19 test approved in t... 17-Feb-2022 ShareCast
Novacyt gets UK approval for 'genesig' Covid-19 ... 26-Nov-2021 ShareCast

Latest NCYT Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

NCYT Market Data

Currency UK Pounds
Share Price 118.70p
Change Today -2.30p
% Change -1.90 %
52 Week High 434.90
52 Week Low 107.50
Volume 70,609
Shares Issued 70.63m
Market Cap £83.83m
RiskGrade 453

NCYT Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
18.27% above the market average18.27% above the market average18.27% above the market average18.27% above the market average18.27% above the market average
21.05% above the sector average21.05% above the sector average21.05% above the sector average21.05% above the sector average21.05% above the sector average
Price Trend
82.7% below the market average82.7% below the market average82.7% below the market average82.7% below the market average82.7% below the market average
73.68% below the sector average73.68% below the sector average73.68% below the sector average73.68% below the sector average73.68% below the sector average
Income Not Available
Growth
22.80% above the market average22.80% above the market average22.80% above the market average22.80% above the market average22.80% above the market average
25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average25.71% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

NCYT Dividends

No dividends found

Trades for 08-Aug-2022

Time Volume / Share Price
16:32 16 @ 123.00p
16:26 742 @ 117.15p
16:20 299 @ 120.10p
16:12 6,389 @ 117.40p
16:12 690 @ 117.45p

NCYT Key Personnel

CFO James McCarthy
CEO David Allmond

Top of Page